The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Diabetes-related foot ulcers (DFUs) and their sequelae result in large patient and societal burdens. Long-term data determining the efficacy of individual glucose-lowering agents on DFUs are lacking. Using existing data from the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, we conducted post hoc analyses assessing the impact of liraglutide versus placebo in people with type 2 diabetes and at high risk of cardiovascular (CV) events on the incidence of DFUs and their sequelae. RESEARCH DESIGN AND METHODS: The LEADER trial (NCT01179048) was a randomized, double-blind, multicenter, CV outcomes trial assessing liraglutide (1.8 mg/day) versus placebo, in addition to standard of care, for up to 5 years. Information on DFUs was collected systematically during the trial, and DFU complications were assessed post hoc through reviewing case narratives. RESULTS: During a median of 3.8 years’ follow-up, similar proportions of patients reported at least one episode of DFU in the liraglutide and placebo groups (3.8% [176/4,668] versus 4.1% [191/4,672], respectively; hazard ratio [HR] 0.92 [95% CI 0.75, 1.13; P = 0.41]). Analysis of DFU-related complications demonstrated a significant reduction in amputations with liraglutide versus placebo (HR 0.65 [95% CI 0.45, 0.95; P = 0.03]). However, no differences were found for foot infections, involvement of underlying structures, or peripheral revascularization in the main analysis. CONCLUSIONS: Treatment with liraglutide in patients with type 2 diabetes and at high risk of CV events in the LEADER trial did not increase the risk of DFU events and was associated with a significantly lower risk of DFU-related amputations compared with placebo. This association, possibly due to chance, needs further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“Diamicron MR Controlled Evaluation (ADVANCE) studies, but DFU was not a specified end point in these trials (11,20,21).”
BackgroundLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“In the Veterans Affairs Diabetes Trial (VADT), amputation due to ischemic gangrene was included within the composite primary end point, but data related to amputation or foot ulcers only do not appear to have been published (22,23).”
BackgroundDiabetic foot ulcers and their recurrence
Armstrong, D. G., Boulton, A. J. M., & Bus, S. A. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1615439 · Cited by 4,376 · cited 7×
“In the longer term, however, there is a high risk that DFUs will recur (1).”
BackgroundInfluentialGupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Ismail-Beigi, F., Craven, T., Banerji, M. A., Basile, J., Calles, J., Cohen, R. M., Cuddihy, R., Cushman, W. C., Genuth, S., Grimm, R. H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60576-4 · Cited by 1,428
Cited by
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia: A Review
Polonsky, T. S., & McDermott, M. M. (2021) · JAMA · doi:10.1001/jama.2021.2126 · Cited by 198
Lower extremity arterial disease in patients with diabetes: a contemporary narrative review
Nativel, M., Potier, L., Alexandre, L., Baillet-Blanco, L., Ducasse, E., Velho, G., Marre, M., Roussel, R., Rigalleau, V., & Mohammedi, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0781-1 · Cited by 194
Bonaca, M. P., Catarig, A.-M., Houlind, K., Ludvik, B., Nordanstig, J., Ramesh, C. K., Rasouli, N., Sourij, H., Videmark, A., & Verma, S. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00509-4 · Cited by 176
“20 Early evidence suggests that the anti-inflammatory effects of GLP-1 receptor agonists extend to the vasculature, 23 and might partly explain the benefits for reducing ischaemic events and a lower rate of amputation observed in one study.”
Contemporary Medical Management of Peripheral Artery Disease
Bonaca, M. P., Hamburg, N. M., & Creager, M. A. (2021) · Circulation Research · doi:10.1161/circresaha.121.318258 · Cited by 161
Diabetic foot ulcer: Challenges and future
Li, Y., Rong, G.-C., & Wu, Q. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i12.1014 · Cited by 187
Creager, M. A., Matsushita, K., Arya, S., Beckman, J. A., Duval, S., Goodney, P. P., Gutierrez, J. A. T., Kaufman, J. A., Joynt Maddox, K. E., Pollak, A. W., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000967 · Cited by 164
Racial and Ethnic Disparities in Peripheral Artery Disease
Hackler, E. L., Hamburg, N. M., & White Solaru, K. T. (2021) · Circulation Research · doi:10.1161/circresaha.121.318243 · Cited by 141
Nreu, B., Dicembrini, I., Tinti, F., Sesti, G., Mannucci, E., & Monami, M. (2020) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.03.013 · Cited by 84
Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
Ponirakis, G., Abdul‐Ghani, M. A., Jayyousi, A., Almuhannadi, H., Petropoulos, I. N., Khan, A., Gad, H., Migahid, O., Megahed, A., DeFronzo, R. A., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001420 · Cited by 83
Birtcher, K. K., Allen, L. A., Anderson, J. L., Bonaca, M. P., Gluckman, T. J., Hussain, A., Kosiborod, M., Mehta, L. S., & Virani, S. S. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.754 · Cited by 86
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Wang, Y., Xiao, D., Yu, H., Ke, R., Shi, S., Tang, Y. H., Zhong, Y. P., Zhang, L., Sui, X., Wang, B., et al. (2022) · Composites Part B Engineering · doi:10.1016/j.compositesb.2022.109762 · Cited by 70
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05497-1 · Cited by 68
Disparities in Diagnosis, Treatment, and Outcomes of Peripheral Artery Disease
McDermott, M. M., Ho, K. J., Alabi, O., Criqui, M. H., Goodney, P. P., Hamburg, N. M., McNeal, D. M., Pollak, A. W., Smolderen, K. G. E., & Bonaca, M. P. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.09.830 · Cited by 71
Caruso, P., Maiorino, M. I., Longo, M., Porcellini, C., Matrone, R., Selvaggio, L. D., Gicchino, M., Carbone, C., Scappaticcio, L., Bellastella, G., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.1545 · Cited by 67
Yu, Z., Li, M., Yang, L., Liu, H., Ding, G., Ma, S., Liu, L., & Dong, S. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102358 · Cited by 64
Badjatiya, A., Merrill, P., Buse, J. B., Goodman, S. G., Katona, B. G., Iqbal, N., Pagidipati, N. J., Sattar, N. A., Holman, R. R., Hernandez, A. F., et al. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008018 · Cited by 72
Self-citationVerma, S., Al‐Omran, M., Leiter, L. A., Mazer, C. D., Rasmussen, S., Saevereid, H. A., Sejersten Ripa, M., & Bonaca, M. P. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14700 · Cited by 61
“Limb events, which are associated with a poor prognosis,(44) were not analysed in this study; because of the protocol and safety data collection methods, it was not possible to analyse all amputations occurring during the trial.(45) We did not evaluate oral”
BackgroundDiabetic peripheral neuropathy in people with type 2 diabetes: too little too late
Javed, S., Hayat, T., Menon, L., Alam, U., & Malik, R. A. (2019) · Diabetic Medicine · doi:10.1111/dme.14194 · Cited by 65
Verma, S., Leiter, L. A., Mangla, K. K., NIELSEN, N. F., Hansen, Y., & Bonaca, M. P. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01606-6 · Cited by 56
Safety of liraglutide in type 2 diabetes and chronic kidney disease
Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11881019 · Cited by 50
“73 m(2) (SD) 46 (11) 46 (11) 91 (22) 91 (22) 74 (30) 75 (29) 84 (26) 84 (26)”
BackgroundResultInfluentialAboyans, V., Canonico, M. E., Chastaingt, L., Anand, S. S., Brodmann, M., Couffinhal, T., Criqui, M. H., Debus, E. S., Mazzolai, L., McDermott, M. M., et al. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00651-0 · Cited by 54
“Among GLP1RAs, liraglutide and semaglutide demonstrated cardiovascular and limb benefits in patients with PAD and T2DM in the LEADER 122 and SUSTAIN-6 trials 123 .”
InfluentialLower extremity artery disease in patients with type 2 diabetes
Buso, G., Aboyans, V., & Mazzolai, L. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319880044 · Cited by 48
Su, J., Wei, Q., Ma, K., Wang, Y., Hu, W., Meng, H., Li, Q., Zhang, Y., Zhang, W., Li, H., et al. (2023) · Burns & Trauma · doi:10.1093/burnst/tkad010 · Cited by 49
“If not properly diagnosed and treated, diabetic foot ulceration results in amputation in 15– 27% of patients [5].”
BackgroundEmerging Frontiers in GLP-1 Therapeutics: A Comprehensive Evidence Base (2025)
Patel, S., & Niazi, S. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17081036 · Cited by 54
“…Suppurativa GLP-1 RAs Hurley stage improvement p = 0.002 [135,136] Wound Healing Liraglutide Healing acceleration Demonstrated in T2DM [137,138] The primary anti-inflammatory mechanisms include the inhibition of JAK-STAT and NF-κ B signaling pathways in keratinocytes, enhanced…”
InfluentialUpdate on prevention of diabetic foot ulcer
Miranda, C., ROS, R. D., & Marfella, R. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.107817 · Cited by 59
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Preoperative evaluation and perioperative management of patients undergoing major vascular surgery
Lee, C., Columbo, J. A., Stone, D. H., Creager, M. A., & Henkin, S. (2022) · Vascular Medicine · doi:10.1177/1358863x221122552 · Cited by 44
Scheen, A. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101325 · Cited by 43
Wu, J., Tu, W., Yu, T., Liao, K., & Lin, Y. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112083 · Cited by 39
Peripheral Artery Disease: Molecular Mechanisms and Novel Therapies
Athavale, A., Fukaya, E., & Leeper, N. J. (2024) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.124.320195 · Cited by 41
Lan, N. S. R., Dwivedi, G., Fegan, P. G., Game, F. L., & Hamilton, E. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02527-1 · Cited by 42
Lin, D. S., Yu, A., Lo, H.-Y., Lien, C.-W., Lee, J., & Chen, W. (2022) · Diabetologia · doi:10.1007/s00125-022-05772-9 · Cited by 40
“A post hoc analysis of the LEADER trial [19] reported the benefits of liraglutide in reducing amputations due to diabetic foot ulcers (DFUs).”
BackgroundMethodBaseline modern medical management in the BEST-CLI trial
Menard, M. T., Jaff, M. R., Farber, A. M., Rosenfield, K., Conte, M. S., White, C. J., Beckman, J. A., Choudhry, N. K., Clavijo, L., Huber, T. S., et al. (2023) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2023.05.006 · Cited by 36
Alasmari, A. F., Ali, N., Alasmari, F. F., Alanazi, W. A., Alshammari, M. A., Al-Harbi, N. O., Alhoshani, A., Sobeai, H. M. A., Alswayyed, M., Alanazi, M. M., et al. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.03.002 · Cited by 34
“Myriad of studies documented the cardioprotective effect of LIRA against different insult (Dhatariya et al., 2018; Garber, 2011; Marso et al., 2016; Noyan-Ashraf et al., 2009; Verma et al., 2018; Zhang et al., 2018).”
Wen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s312527 · Cited by 30
“Due to the current limited studies and related sample size, the risks of complication of diabetic foot in SGLT-2is is not clear, but are not with GLP-1RA.(39,40) In addition, there were no strong clinical evidences showing the application of either GLP1RA or SGLT-2i has the positive effect on the diabetic retinopathy.”
BackgroundMahé, G., Aboyans, V., Cosson, E., Mohammedi, K., Sarlon-Bartoli, G., Lanéelle, D., Mirault, T., & Darmon, P. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02325-9 · Cited by 34
“…in 9340 patients with T2DM at high cardiovascular risk, found that treatment with liraglutide did not increase the risk of DFUs (defined as an open wound on the foot) and was associated with a significantly lower risk of DFU-related amputations compared to placebo (HR 0.65; 95% CI 0.45–0.95) [ 41].”
BackgroundInfluentialOlesen, K. K. W., Gyldenkerne, C., Thim, T., Thomsen, R. W., & Maeng, M. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001803 · Cited by 28
Wang, F., Zhang, X., Zhang, J., Xu, Q., Yu, X., Xu, A., Yi, C., Bian, X., & Shao, S. (2024) · Medicinal Research Reviews · doi:10.1002/med.22020 · Cited by 33
Hong, A. T., Luu, I. Y.-K., Lin, F., Shin, L., Hsu, C., Shih, C.-D., Armstrong, D. G., & Tan, T. (2025) · Diabetes Care · doi:10.2337/dc25-0292 · Cited by 31
Piechocki, M., Przewłocki, T., Pieniążek, P., Trystuła, M., Podolec, J., & Kabłak-Ziembicka, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051508 · Cited by 34
“They enhance insulin secretion in response to a carbohydrate-containing meal and prevent postprandial hyper-glycemia [164,167–169].”
BackgroundResultHeiß, C., Olinic, D.-M., Belch, J. J. F., Brodmann, M., Mazzolai, L., Stanek, A., Maďarič, J., Krentz, A. J., Schlager, O., Lichtenberg, M. K. W., et al. (2022) · VASA · doi:10.1024/0301-1526/a000998 · Cited by 29
Werkman, N. C. C., Driessen, J. H. M., Stehouwer, C. D. A., Vestergaard, P., Schaper, N. C., van den Bergh, J. P., & Nielen, J. T. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01897-2 · Cited by 31
Liarakos, A. L., Tentolouris, A., Kokkinos, A. D., Eleftheriadou, I., & Tentolouris, N. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108390 · Cited by 30
Bonaca, M. P., Catarig, A., Hansen, Y., Houlind, K. C., Ramesh, C. K., Ludvik, B. H., Nordanstig, J., Rasouli, N., Sourij, H., & Verma, S. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae071 · Cited by 26
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26
Hsiao, F., Lin, C., Tung, Y., Wu, C.-T., & Chu, P. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109076 · Cited by 26
Liraglutide Promotes Diabetic Wound Healing via Myo1c/Dock5
Zhang, Q., Zhang, C., Kang, C., Zhu, J., He, Q., Li, H., Tong, Q., Wang, M., Zhang, L., Xiong, X., et al. (2024) · Advanced Science · doi:10.1002/advs.202405987 · Cited by 34
Managing thrombotic risk in patients with diabetes
Camm, A. J., Sabbour, H. M., Schnell, O., Summaria, F., & Verma, A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01581-x · Cited by 28
“For example, liraglutide reduced the risk of amputations associated with diabetes-related foot ulcerations compared with placebo in patients with type 2 diabetes and a high risk of CV events [124].”
BackgroundDiagnosing and managing diabetic somatic and autonomic neuropathy
Azmi, S., Ferdousi, M., Kalteniece, A., Almuhannadi, H., Al‐Mohamedi, A., Hadid, N. H., Mahmoud, S., Bhat, H., Gad, H., Khan, A., et al. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819826890 · Cited by 23
Microvascular disease increases the risk of lower limb amputation – A Western Danish cohort study
Olesen, K. K. W., Anand, S., Thim, T., Gyldenkerne, C., & Maeng, M. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13812 · Cited by 21
Skeik, N., Elejla, S. A., Sethi, A., Manunga, J. M., & Mirza, A. K. (2023) · Vascular Medicine · doi:10.1177/1358863x221143811 · Cited by 22
Foussard, N., Dari, L., Ducasse, É., Rigalleau, V., Mohammedi, K., & Caradu, C. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104164 · Cited by 21
Lü, Y., & Guo, C. (2023) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986231178126 · Cited by 21
Incretin‐based therapy and the risk of diabetic foot ulcers and related events
Werkman, N. C. C., Driessen, J. H. M., Klungel, O. H., Schaper, N. C., Souverein, P. C., Stehouwer, C. D. A., & Nielen, J. T. H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15721 · Cited by 20
“26 which was replicated in the current study versus insulin, with a very similar effect size.”
Gruzmark, F. S., Beraja, G. E., Jozic, I., & Lev‐Tov, H. A. (2025) · Wound Repair and Regeneration · doi:10.1111/wrr.70085 · Cited by 17
“In the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial, the GLP-1RA li-raglutide was associated with a 35% reduction in the risk of LEAs related to diabetic foot ulcers compared to placebo [119].”
Tehan, P. E., Burrows, T. L., Hawes, M. B., Linton, C., Norbury, K., Peterson, B. J., Walsh, A., White, D., & Chuter, V. (2022) · Diabetic Medicine · doi:10.1111/dme.14951 · Cited by 20
“Failed 2 or more neurological tests, n (%) 92 (78) 45 (75) 47 (85) 0.”
Rasouli, N., Arslan, E. G., Catarig, A., Houlind, K. C., Ludvik, B. H., Nordanstig, J., Sourij, H., Thomas, S., Verma, S., & Bonaca, M. P. (2025) · Diabetes Care · doi:10.2337/dc25-1082 · Cited by 18
Muzurović, E. M., & Mikhailidis, D. P. (2020) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248420941675 · Cited by 17
“03) versus placebo.(80) Semaglutide treatment (0.”
Caruso, P., Maiorino, M. I., Longo, M., Maio, A., Scappaticcio, L., Martino, N. D., Carbone, C., Barrasso, M., Caputo, M., Gicchino, M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16419 · Cited by 17
“32 However, a post hoc analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial 9 found that lir-aglutide was associated with reduced amputations compared with placebo.”
Go, C. C., Annie, F., Drabish, K., & Eslami, M. H. (2025) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2025.05.037 · Cited by 16
Schäfer, Z., Mathisen, A., Thomsen, T. R., Rossing, P. R., & Kirketerp‐Møller, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110799 · Cited by 15
Up and down waves of glycemic control and lower-extremity amputation in diabetes
Caruso, P., Scappaticcio, L., Maiorino, M. I., Esposito, K., & Giugliano, D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01325-3 · Cited by 15
Rastogi, A., Sudhayakumar, A., Schaper, N. C., & Jude, E. B. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102875 · Cited by 16
Farber, A. M., Menard, M. T., Bonaca, M. P., Bradbury, A. W., Conte, M. S., Debus, E. S., Eldrup, N., Goodney, P. P., Gupta, P. C., Hinchliffe, R. J., et al. (2024) · British journal of surgery · doi:10.1093/bjs/znad413 · Cited by 14
Shao, Z., Zhang, X., Cai, J., & Lu, F. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04369-4 · Cited by 14
“Notably, GLP-1 significantly improves diabetic foot-related lower limb amputation risk in clinical applications [110, 111].”
Diabetes: the place of new therapies
Dhatariya, K. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818807599 · Cited by 14
Self-citationProgress in anti-ageing drug research for age-related diseases: A review
Zhou, Z., Duan, H.-T., Xue, S.-T., & Li, Z. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102982 · Cited by 15
Pleiotropic effects of GLP‐1 receptor agonists on peripheral artery disease: Is there any hope?
Caruso, P., Maiorino, M. I., Bellastella, G., Esposito, K., & Giugliano, D. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3627 · Cited by 13
“reported a reduction in lower limb amputations in people assigned to liraglutide.(15) GLP‐1RAs may improve arterial stiffness and determine systemic microcirculatory benefits in the peripheral vascular district (Figure 1).”
BackgroundMedical Therapy for Peripheral Artery Disease
Canonico, M. E., Hess, C. N., Rogers, R. K., & Bonaca, M. P. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02065-y · Cited by 14
“Moreover, further data on LEADER trial highlighted the lower risk of amputation as diabetes related foot ulcer complication (HR 0.65; 95% CI 0.45–0.95) [ 50].”
InfluentialFelício, J. S., de Melo, F. T. C., Vieira, G. M., de Aquino, V. T., Parente, F. D. S., da Silva, W. M., Said, N. M., da Silva, E. R., de Souza, A. C. C. B., de Oliveira, M. C. N. I., et al. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02722-6 · Cited by 14
Caruso, P., Angelino, S., Matrone, R., Scappaticcio, L., Longo, M., Volatile, A., Petrizzo, M., Pontillo, A., Caputo, M., Carbone, C., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16594 · Cited by 11
“17 Both the STARDUST 9 and the STRIDE 10 trials were specifically designed to evaluate the effect of lir-aglutide and semaglutide, respectively, in people with T2DM and PAD.”
Cimellaro, A., Cavallo, M., Mungo, M., Suraci, E., Spagnolo, F., Addesi, D., Pintaudi, M., & Pintaudi, C. (2024) · Medicina · doi:10.3390/medicina60091542 · Cited by 12
Masson, W. M., Lobo, M., Barbagelata, L., Molinero, G., & Bluro, I. M. (2021) · Vascular · doi:10.1177/17085381211043952 · Cited by 10
“The use of glucagon-like peptide-1 agonists showed a decreased risk of amputation that was not observed with other hypoglycemic agents including insulin.(34,35) Therefore, the results of the present study highlight the importance of strengthening medical training and the need to educate patients in the knowledge of th…”
ResultFocus on Prevention: Peripheral Arterial Disease and the Central Role of the Cardiologist
Fioretti, V., Gerardi, D., Giugliano, G., Fazio, A. D., & Stabile, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134338 · Cited by 11
Kristensen, F., Christensen, D. H., Callaghan, B. C., Nielsen, J. S., Andersen, H., Sørensen, H. T., & Thomsen, R. W. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-01262 · Cited by 9
Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials
Cesaro, A., Acerbo, V., Longo, M., Antonucci, A., Maiorino, M. I., Monaco, M. G., Martelli, E., Giudice, G., Esposito, K., Giorgino, F., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag077 · Cited by 10
Management of diabetic foot disease
Vas, P. R. J., & Kavarthapu, V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820669-0.00004-9 · Cited by 9
Weissler, E. H., Clare, R. M., Lokhnygina, Y. V., Buse, J. B., Goodman, S. G., Katona, B. G., Iqbal, N., Pagidipati, N. J., Sattar, N. A., Holman, R. R., et al. (2021) · Diabetic Medicine · doi:10.1111/dme.14552 · Cited by 10
Self-citationFrom MASLD to PAD: Looking for Cardiovascular Disease Starting from Metabolic Status
Boccatonda, A., D’Ardes, D., Moronti, V., Santilli, J., Cipollone, A., Lessiani, G., Gregorio, N. D., Serra, C., Piscaglia, F., Ferri, C., et al. (2024) · Medicina · doi:10.3390/medicina60111781 · Cited by 10
Kim, S. H., Sung, K., Lee, S. K., Park, J., Kim, N. H., Kim, S. H., & Shin, C. (2019) · Diabetes and Vascular Disease Research · doi:10.1177/1479164119843760 · Cited by 9
Garagoli, F., Masson, W. M., Barbagelata, L., & Lobo, M. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endinu.2025.501562 · Cited by 13
Advances for the treatment of lower extremity arterial disease associated with diabetes mellitus
Pan, Y., Luo, Y., Hong, J., He, H., Dai, L., Zhu, H., & Wu, J. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.929718 · Cited by 7
“ABI ankle-brachial index ACEIs angiotensin-converting enzyme inhibitors ADSCs adipose-derived stem cells AGEs advanced glycation end products apoB apolipoprotein B ARBs angiotensin receptor antagonists bFGF/FGF-2 basic fibroblast growth factor BMMNCs bone marrow mononuclear cells BMMSCs bone marrow mesenchymal stem ce…”
BackgroundLifestyle Approach and Medical Therapy of Lower Extremity Peripheral Artery Disease
Krittanawong, C., Escobar, J., Virk, H. U. H., Alam, M., Virani, S. S., Lavie, C. J., Narayan, K. M. V., & Sharma, R. M. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.10.028 · Cited by 7
HIGHTON, P. J., Almaqhawi, A., Oroko, M., Sathanapally, H., Gray, L. J., Davies, M. J., Webb, D. R., Game, F. L., Petrie, J. R., Tesfaye, S. H., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111590 · Cited by 6
“These include but are not limited to nutritional strategies [15], drug-based interventions [16], and alternative methods or models for care delivery [17,18].”
Diabetic foot: clinical approach
Caruso, I., Leonardini, A., Caizzi, G., Vicenti, G., Caporusso, M., Guarini, F., Bernardis, M., Moretti, B., & Giorgino, F. (2022) · Minerva Orthopedics · doi:10.23736/s2784-8469.21.04108-0 · Cited by 6
Al-Qurain, A. A., Salem, M., Algarzai, B. A., Eljadi, E. M., Elsayed, H., Almuhanna, A., Albuhayji, D. S., Salami, M., Alzahrani, J. A., Alsayyali, J., et al. (2026) · Cureus · doi:10.7759/cureus.100927 · Cited by 7
Liposome/Exosome Hybrid Loaded with FGF2 mRNA for Diabetic Wound Healing
Wang, M., Xue, W., liu, J., Jiang, Y., Luo, J., Shi, S., Yin, X., & Li, X. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c25924 · Cited by 6
Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
Li, Q., Yu, S., Rui, S., Lin, X., Yuan, Y. C., Armstrong, D. G., Xu, Y., & Deng, W. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1581403 · Cited by 5
Role of Dipeptidyl Dipeptidase 4 Inhibitors in the Management of Diabetic Foot
Yu, W., Zhang, T., & Xu, H. (2022) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346221082776 · Cited by 5
“29 After the observance of a high amputation rate in the canagli fl ozin group in comparison with placebo in a randomized controlled trial, 30 a meta-analysis did not fi nd an increased risk of amputation with SGLT2 inhibitors.”
GLP-1 Receptor Agonists Help Legs
Goldenberg, R., & Verma, S. (2025) · Diabetes Care · doi:10.2337/dci25-0070 · Cited by 5
Walking Further with GLP-1RAs: Lessons from the STRIDE Trial
Pantazopoulos, D., Papachristou, S., Vas, P. R. J., & Παπάνας, Ν. (2025) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346251385584 · Cited by 4
“19 It has been hypothesised that in fl ammation might play an important role in claudication through effects on shunting, vasoconstriction and changes in blood viscosity.”
Elliott, B., Tomlinson, E., Desai, N., Heald, A. H., Field, B. C. T., Heiß, C., & Whyte, M. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01843-x · Cited by 3
GLP-1 Receptor Agonist Use Is Associated with Venous Ulcer Healing and Fewer Wound Infections
Go, C. C., Annie, F., Drabish, K., & Eslami, M. H. (2026) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2026.03.023 · Cited by 4
Boccatonda, A., D’Ardes, D., Brighenti, A., Cipollone, A., Simeone, P., Guagnano, M. T., Serra, C., Santilli, F., & Cipollone, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113271 · Cited by 3
Does Improvement of Glycemic Control Cause Acute Charcot Foot in Patients with Diabetes?
Svendsen, O. L., & Jansen, R. B. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2498-6826 · Cited by 3
Dascălu, A. M., Şerban, D., Παπάνας, Ν., Kempler, P., Rizzo, M., Stana, D., Román, G., & Stoian, A. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96548 · Cited by 3
Glucagon‐like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?
Giugliano, D., Caruso, P., Maiorino, M. I., Bellastella, G., & Esposito, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70246 · Cited by 2
“In 2018, Dhatariya et al. 9 published a post hoc analysis of the LEADER trial demonstrating a 35% significant reduction of amputation with liraglutide versus placebo in patients with type 2 diabetes and at high risk of CV events.”
Metadata
- Authors
- Dhatariya, K., Bain, S. C., Buse, J. B., Simpson, R., Tarnow, L., Kaltoft, M. S., Stellfeld, M., Tornøe, K., Pratley, R. E., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators
- Affiliations
- Norfolk and Norwich University Hospital (GB)
- University of East Anglia (GB)
- Corresponding author
- Dhatariya, Ketan
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-08-02
- Volume
- 41
- Issue
- 10
- Pages
- 2229-2235
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC6150424
- OpenAlex
- W2883426762
- Semantic Scholar
- 27723cc2089089c747770bb1f4a89c5cf9dd9df2
- Cited by
- 141
- References
- 30
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 19 · 2023: 20 · 2022: 21 · 2021: 16 · 2020: 10 · 2019: 10 · 2018: 2
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- liraglutide, diabetic foot ulcer, type 2 diabetes, amputation, foot infection, peripheral revascularization, cardiovascular risk, GLP-1 receptor agonists, LEADER trial, post hoc analysis
- MeSH terms
- Liraglutide, Aged, Amputation, Surgical, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Diabetic Foot
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.